CRYOPORT, INC. (CYRX) Spending and interest coverage
- R&D / revenue · 12 months: Value 9.52%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 5.23%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 9.52% | Research and development expense / revenue. Period ending 2026-06-30. $17.75M ÷ $186.45M × 100 ≈ 9.52% |
| Stock-based compensation / revenue · 12 months | 5.23% | Share-based compensation / revenue. Period ending 2026-06-30. $9.75M ÷ $186.45M × 100 ≈ 5.23% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 17.75M USD | Research and Development Expense |
| Revenue | 186.45M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.75M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -39.62M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $17.75M | $186.45M | $9.75M | $-39.62M | (m) | 9.52% | 5.23% | (m) | (m) |
| 2026-03-31 | $17.01M | $182.94M | $9.40M | $-39.23M | (m) | 9.30% | 5.14% | (m) | (m) |
| 2025-12-31 | $17.04M | $176.18M | $10.07M | $-36.81M | (m) | 9.67% | 5.71% | (m) | (m) |
| 2025-09-30 | $16.73M | $243.79M | $14.42M | $-48.72M | (m) | 6.86% | 5.91% | (m) | (m) |
| 2025-06-30 | $16.36M | $237.88M | $15.95M | $-52.17M | (m) | 6.88% | 6.70% | (m) | (m) |
| 2025-03-31 | $16.89M | $232.13M | $18.10M | $-122.84M | (m) | 7.28% | 7.80% | (m) | (m) |
| 2024-12-31 | $17.71M | $228.38M | $19.70M | $-130.87M | (m) | 7.75% | 8.63% | (m) | (m) |
| 2024-09-30 | $18.30M | $226.11M | $21.14M | $-186.81M | (m) | 8.10% | 9.35% | (m) | (m) |
| 2024-06-30 | $19.30M | $225.61M | $22.28M | $-187.29M | (m) | 8.55% | 9.87% | (m) | (m) |
| 2024-03-31 | $18.92M | $225.03M | $23.08M | $-126.39M | $5.33M | 8.41% | 10.26% | -23.70× | Reported |
| 2023-12-31 | $18.04M | $233.25M | $22.81M | $-115.16M | $5.50M | 7.73% | 9.78% | -20.93× | Reported |
| 2023-09-30 | $17.97M | $236.35M | $22.29M | $-56.32M | $5.65M | 7.60% | 9.43% | -9.96× | Reported |
| 2023-06-30 | $16.80M | $240.66M | $21.68M | $-47.22M | $5.91M | 6.98% | 9.01% | -8.00× | Reported |
| 2023-03-31 | $16.06M | $247.79M | $21.14M | $-34.13M | $6.16M | 6.48% | 8.53% | -5.54× | Reported |
| 2022-12-31 | $15.72M | $237.28M | $20.08M | $-31.90M | $6.14M | 6.63% | 8.46% | -5.19× | Reported |
| 2022-09-30 | $14.94M | $233.36M | $18.93M | $-29.23M | $5.81M | 6.40% | 8.11% | -5.03× | Reported |
| 2022-06-30 | $15.14M | $229.59M | $17.71M | $-26.00M | $5.39M | 6.59% | 7.72% | -4.82× | Reported |
| 2022-03-31 | $16.08M | $221.63M | $16.48M | $-24.51M | $4.97M | 7.25% | 7.44% | -4.93× | Reported |
| 2021-12-31 | $16.84M | $222.61M | $15.35M | $-17.83M | $4.69M | 7.57% | 6.89% | -3.80× | Reported |
| 2021-09-30 | $16.45M | $214.53M | $4.82M | $-19.31M | $3.83M | 7.67% | 2.25% | -5.04× | Reported |
| 2021-06-30 | $14.57M | $169.01M | $3.10M | $-25.47M | $4.53M | 8.62% | 1.84% | -5.62× | Reported |
| 2021-03-31 | $12.05M | $122.21M | $1.38M | $-27.57M | $3.77M | 9.86% | 1.13% | -7.32× | Reported |
| 2020-12-31 | $9.48M | $78.70M | $8.92K | $-30.01M | $2.56M | 12.05% | 0.01% | -11.72× | Reported |
| 2020-09-30 | $7.06M | $39.58M | $6.74M | $-21.04M | $1.93M | 17.84% | 17.02% | -10.91× | Reported |
| 2020-06-30 | $6.39M | $37.99M | $17.04M | $-22.66M | $1.09M | 16.82% | 44.86% | -20.70× | Reported |
| 2020-03-31 | $4.98M | $37.06M | $16.73M | $-19.12M | $1.03M | 13.45% | 45.14% | -18.55× | Reported |
| 2019-12-31 | $3.74M | $33.94M | $16.52M | $-17.68M | $1.37M | 11.02% | 48.68% | -12.93× | Reported |
| 2019-09-30 | $3.27M | $30.39M | $17.63M | $-19.02M | $990.30K | 10.76% | 58.00% | -19.20× | Reported |
| 2019-06-30 | $2.09M | $26.09M | $6.39M | $-8.83M | $741.89K | 8.02% | 24.49% | -11.90× | Reported |
| 2019-03-31 | $2.00M | $22.26M | $5.84M | $-8.99M | $407.98K | 8.99% | 26.25% | -22.03× | Reported |
| 2018-12-31 | $1.84M | $19.63M | $5.48M | $-8.64M | $69.25K | 9.38% | 27.91% | -124.83× | Reported |
| 2018-09-30 | $1.62M | $17.26M | $5.01M | $-8.70M | $0.00 | 9.40% | 29.04% | (m) | Reported |
| 2018-06-30 | $1.50M | $14.97M | $4.48M | $-8.52M | $0.00 | 10.04% | 29.90% | (m) | Reported |
| 2018-03-31 | $1.29M | $13.27M | $3.83M | $-7.92M | $26.00 | 9.69% | 28.85% | -304672.85× | Reported |
| 2017-12-31 | $1.21M | $11.95M | $3.55M | $-7.89M | $15.69K | 10.09% | 29.68% | -502.93× | Reported |
| 2017-09-30 | $928.53K | $10.86M | $3.31M | $-7.62M | $33.37K | 8.55% | 30.47% | -228.46× | Reported |
| 2017-06-30 | $798.41K | $9.84M | $3.14M | $-7.80M | $52.67K | 8.12% | 31.97% | -148.01× | Reported |
| 2017-03-31 | $703.47K | $8.84M | $3.10M | $-7.91M | $73.89K | 7.96% | 35.08% | -107.07× | Reported |
| 2016-12-31 | $598.11K | $7.68M | $3.16M | $-8.77M | $139.42K | 7.79% | 41.10% | -62.88× | Reported |
| 2016-09-30 | $722.72K | $6.91M | $3.32M | $-9.44M | $201.69K | 10.46% | 47.99% | -46.82× | Reported |
| 2016-06-30 | $608.34K | $6.37M | $3.15M | $-9.10M | $783.38K | 9.55% | 49.51% | -11.62× | Reported |
| 2016-03-31 | $550.26K | $5.88M | $2.88M | $-8.74M | $1.07M | 9.35% | 49.03% | -8.20× | Reported |
| 2015-12-31 | $490.79K | $5.53M | $2.37M | $-7.81M | $1.23M | 8.88% | 42.96% | -6.36× | Reported |
| 2015-09-30 | $362.08K | $5.04M | $1.65M | $-6.49M | $1.20M | 7.18% | 32.63% | -5.42× | Reported |
| 2015-06-30 | $351.06K | $4.43M | $1.19M | $-6.04M | $602.94K | 7.92% | 26.98% | -10.02× | Reported |
| 2015-03-31 | $352.58K | $3.94M | $881.71K | $-5.59M | $1.43M | 8.96% | 22.40% | -3.92× | Reported |
| 2014-12-31 | $347.12K | $3.57M | $733.37K | $-5.17M | $1.34M | 9.72% | 20.53% | -3.85× | Reported |
| 2014-09-30 | $366.56K | $3.35M | $701.35K | $-5.07M | $1.33M | 10.93% | 20.91% | -3.83× | Reported |
| 2014-06-30 | $395.71K | $3.11M | $688.01K | $-4.99M | $1.83M | 12.73% | 22.13% | -2.72× | Reported |
| 2014-03-31 | $409.11K | $2.66M | $678.12K | $-5.08M | $784.45K | 15.38% | 25.49% | -6.47× | Reported |
| 2013-12-31 | $449.98K | $2.19M | (m) | $-5.48M | $651.39K | 20.51% | (m) | -8.42× | Reported |
| 2013-09-30 | $425.92K | $1.74M | (m) | $-5.78M | $631.50K | 24.43% | (m) | -9.15× | Reported |
| 2013-06-30 | $409.14K | $1.40M | (m) | $-6.04M | $130.48K | 29.28% | (m) | -46.32× | Reported |
| 2013-03-31 | $425.45K | $1.10M | (m) | $-6.32M | $72.86K | 38.66% | (m) | -86.80× | Reported |
| 2012-12-31 | $450.24K | $908.97K | (m) | $-6.11M | $255.97K | 49.53% | (m) | -23.89× | Reported |
| 2012-09-30 | $476.52K | $746.07K | (m) | $-6.63M | $323.04K | 63.87% | (m) | -20.51× | Reported |
| 2012-06-30 | $499.57K | $623.18K | (m) | $-7.02M | $419.04K | 80.16% | (m) | -16.74× | Reported |
| 2012-03-31 | $491.85K | $555.64K | (m) | $-7.43M | $527.75K | 88.52% | (m) | -14.09× | Reported |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $449.13K | $475.50K | (m) | $-5.60M | $618.76K | 94.45% | (m) | -9.05× | Reported |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |